Abstract
4267 Background: Raltitrexed (RX), oxaliplatin (OX) and 5-FU have shown synergistic and addictive activity against gastrointestinal cancer. The objective of the study was to evaluated the efficacy and toxicity of this combination and find the best oxaliplatin dose. Methods: Between april 2001 and april 2003 23 patients (pts) with MGC and LAGC (16 gastric and 7 colorectal cancer) were treated every 3 weeks with: day 1 RX 2,5 mg/m2, followed by OX 85 mg / m2 (after third cycle if no grade 3 or 4 toxicity increased to 100 mg/m2). 5-FU 1000 mg/m2 24hs continuos infusion, initiated after OX and lasted for 3 days modulated with leucovorin 50 mg each 6 hours. Pts: 13 male/10 female median age 64, 19 pts with more than one site of metastasis (mets). (9 pts with carcinomatosis and 9 with liver mets. Results: Toxicity: 5 pts experienced grade 3/4 stomatites and/or diarrhea. Only 2 pts with grade 3/4 leucopenia and 1 pt with neurotoxicity grade 3. Response: 19 pts were evaluated for response. CR-10.5% PR 52,5% SD- 21 % and Progr.16%. Median duration of response 7 months; median survival 16+ months, with 11 pts still alive. Conclusions: ROLF is an active scheme advanced gastric and colon cancer with low toxicity and in 40% pts a dose of 100 mg/m2 of OX is safe and could improve response. No significant financial relationships to disclose.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
